A review of testing used in seroprevalence studies on measles and rubella |
| |
| Affiliation: | 1. NRL, 4th Floor Healy Building, 41 Victoria Parade, Fitzroy 3065, Victoria, Australia;2. World Health Organization, Global VPD Laboratory Networks, 20, Avenue Appia, CH-1211 Geneva 27, Switzerland;1. Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA;2. Mayo Clinic Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA;3. Mayo Clinic Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA;1. Division of Vaccine Research, Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea;2. Division of Viral Disease, Center for Laboratory Control of Infectious Disease, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea;3. Korea National Research Institute of Health, Korea Centers for Disease Control and Prevention, CheongJu, Chungcheongbuk-do, Republic of Korea;1. Surveillance and Assessment, Alberta Ministry of Health, Edmonton, AB, Canada;2. Department of Pediatrics, University of Alberta, Edmonton, AB, Canada;3. Department of Microbiology, Immunology & Infectious Diseases (MIID), University of Calgary, Calgary, AB, Canada;4. Provincial Laboratory for Public Health (ProvLab), Calgary, AB, Canada;5. DynaLIFEDX Diagnostic Laboratory Services, Edmonton, AB, Canada;6. Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada;7. Public Health Agency of Canada, Ottawa, ON, Canada;8. Communicable Disease Control, Alberta Health Services, Edmonton, AB, Canada;9. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada;1. MEPHI, IRD, APHM, IHU-Méditerranée Infection, Aix-Marseille University, 13005 Marseille, France;2. VITROME, IRD, APHM, IHU-Méditerranée Infection, Aix-Marseille University, 13005 Marseille, France;1. Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands;2. Laboratory Medical Microbiology, Tergooi Hospital, Hilversum, The Netherlands;3. Department of Medical Microbiology, Bronovo Hospital, The Hague, The Netherlands;4. Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands;5. Department of Viroscience, Erasmus University MC, Rotterdam, The Netherlands |
| |
| Abstract: | Seroprevalence studies are an essential tool to monitor the efficacy of vaccination programmes, to understand population immunity and to identify populations at higher risk of infection. An overarching review of all aspects of seroprevalence studies for measles and rubella published between 1998 and June 2014 was undertaken and the findings reported elsewhere. This paper details the considerable variation in the testing formats identified in the review. Apart from serum/plasma samples, testing of oral fluid, breast milk, dry blood spots and capillary whole blood were reported. Numerous different commercial assays were employed, including microtitre plate assays, automated immunoassays and classical haemagglutination inhibition and neutralisation assays. A total of 29 of the 68 (43%) measles and 14 of the 58 (24%) rubella studies reported qualitative test results. Very little information on the testing environment, including quality assurance mechanisms used, was provided. Due to the large numbers of testing systems, the diversity of sample types used and the difficulties in accurate quantification of antibody levels, the results reported in individual studies were not necessarily comparable. Further efforts to standardise seroprevalence studies may overcome this deficiency. |
| |
| Keywords: | Seroprevalence Measles Rubella |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
